All In Biotech

Drug Trial Radar · NCT01928888

Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes

A Randomized, Double-blind, Three-fold Cross-over, Multi-center Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid (1000 mg Hydrotalcite), a Single Dose of Oral Famotidine 10 mg, and a Single Dose of Placebo in Patients With Acute Heartburn Episodes.

Last checked: Nov 19, 2026Latest source record: Dec 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 559 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

559

Actual

Start

May 2003

Primary completion

Feb 2004

Study completion Feb 2004

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Aug 27, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of a single oral administration of 1000 mg Talcid® (study medication), a single oral administration of 10 mg famotidine and a single oral administration of placebo (comparator without an active substance) in treating the symptoms of acute heartburn episodes. The study is designed to collect more efficacy data on Talcid® in patients using self-medication to relief the symptoms of acute heartburn.

Conditions

  • Heartburn

Interventions

  • Talcid (Hydrotalcite, BAY4516H)Drug

    2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine

  • FamotidineDrug

    2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg

  • PlaceboDrug

    2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total heartburn relief over 0-60 minTime frame: up to 60 minutes

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Ask Central Contact, Germany

  • Site not named

    Frankfurt am Main, Hesse, Germany

  • Site not named

    Dresden, Saxony, Germany

  • Site not named

    Leipzig, Saxony, Germany

  • Site not named

    Berlin, State of Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.